At a glance
ClinicalIndex Comparison RecordN/ACompleted· 9 enrolled
Drug / intervention
Administration of CANTAB and Subject Global Assessmentother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, 165-302
In Brief
An observational study evaluating Administration of CANTAB and Subject Global Assessment for Phenylketonuria. Completed, enrolled 9 participants across 4 sites.
Detailed Summary
A Phase 3 substudy to evaluate executive function in adults with phenylketonuria who are participating in the phase 3 Study, 165-302. Approximately 100 subjects, aged ≥ 18 to ≤ 70 years old, with PKU will be enrolled.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPhenylketonuria
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartAug 2015
Primary CompletionFeb 2017
TodayJul 2026
First PostedJun 11, 2015
Enrollment StartAug 5, 2015
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.1 years ago
Interventions
Administration of CANTAB and Subject Global Assessmentother
At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire